Trial Profile

A clinical study of TC 220 for cancer patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TC 220 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

23 Aug 2023 As per MR, clinical trials for Alphabeam and proprietary boron-containing drugs are expected to commence in the United States and Europe in 2024. From this its not clear whether this trial is in single country or its a multinational. As of now I have indexed both countries.
23 Aug 2023 New trial record
15 Aug 2023 According to TAE Life Sciences media release, the company expected to commence the trial in the United States and Europe in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com